|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2006-12-13
|
|
pubmed:abstractText |
The treatment of the rheumatological manifestations associated with hepatitis C virus (HCV) remains difficult. To examine the safety of anti-tumour necrosis factor-alpha treatment, nine patients having rheumatological manifestations associated with HCV were treated with etanercept 25 mg twice a week for 3 months.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1462-0324
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
46
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
97-9
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16720634-Antirheumatic Agents,
pubmed-meshheading:16720634-Female,
pubmed-meshheading:16720634-Hepacivirus,
pubmed-meshheading:16720634-Hepatitis C, Chronic,
pubmed-meshheading:16720634-Humans,
pubmed-meshheading:16720634-Immunoglobulin G,
pubmed-meshheading:16720634-Immunologic Factors,
pubmed-meshheading:16720634-Joint Diseases,
pubmed-meshheading:16720634-Male,
pubmed-meshheading:16720634-Middle Aged,
pubmed-meshheading:16720634-Prospective Studies,
pubmed-meshheading:16720634-Receptors, Tumor Necrosis Factor,
pubmed-meshheading:16720634-Severity of Illness Index,
pubmed-meshheading:16720634-Viral Load
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Etanercept treatment for three months is safe in patients with rheumatological manifestations associated with hepatitis C virus.
|
|
pubmed:affiliation |
Clinical Immunology Unit, Department of Immunology, Edouard Herriot Hospital, France.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|
